High materiality8/10
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
BofA upgraded FULC ahead of phase 3 losmapimod readout. Key opinion leaders optimistic on phase 3 results for FSHD. Price target increased from $5 to $10 following analysis. BofA raised likelihood of success for losmapimod from 35% to 50%. Competition may arise from Avidity and Roche in FSHD treatment.
- BofA upgraded FULC ahead of phase 3 losmapimod readout.
- Key opinion leaders optimistic on phase 3 results for FSHD.
- Price target increased from $5 to $10 following analysis.
- BofA raised likelihood of success for losmapimod from 35% to 50%.
- Competition may arise from Avidity and Roche in FSHD treatment.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.